CLOSE ×

Inotiv offers the Wistar Institute Melanoma (WM) PDX model collection established from targeted therapy relapsed melanoma patients, spanning BRAF inhibitors, BRAK/MEK inhibitors, immune checkpoint inhibitors and targeted therapy and immunotherapy (TT/IT) combinations.

  • Vials of cells available
  • In vivo propagation
  • Efficacy studies

 

Read about testing second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived xenograft (PDX) models in Clinical Cancer Research by Krepler et al.

Further reading:

Xiao et al. (2019). A Melanoma Patient-Derived Xenograft Model. Journal of visualized experiments : JoVE, (147), 10.3791/59508. https://doi.org/10.3791/59508

 

Search the WHIM Breast Cancer PDX Models

Search the Wistar Institute Melanoma (WM) PDX Models

Order today

+1 800 793 7287

Online order  

Subscribe to updates from Inotiv

Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.

Subscribe now